These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31730343)

  • 1. Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader.
    Wei J; Hu J; Wang L; Xie L; Jin MS; Chen X; Liu J; Jin J
    J Med Chem; 2019 Dec; 62(23):10897-10911. PubMed ID: 31730343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
    Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
    J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
    Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
    Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
    Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
    Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD.
    Kurian N; Cohen TS; Öberg L; De Zan E; Skogberg G; Vollmer S; Baturcam E; Svanberg P; Bonn B; Smith PD; Vaarala O; Cunoosamy DM
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2611-2624. PubMed ID: 32063702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
    Van Dort ME; Hong H; Wang H; Nino CA; Lombardi RL; Blanks AE; Galbán S; Ross BD
    J Med Chem; 2016 Mar; 59(6):2512-22. PubMed ID: 26943489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models.
    Chiacchiera F; Grossi V; Cappellari M; Peserico A; Simonatto M; Germani A; Russo S; Moyer MP; Resta N; Murzilli S; Simone C
    Cancer Lett; 2012 Nov; 324(1):98-108. PubMed ID: 22579651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
    Mallon R; Feldberg L; Kim S; Collins K; Wojciechowicz D; Kohler C; Kovacs D; Discafani C; Zhang N; Wu B; Floyd B; Powell D; Berger D
    Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
    Kwon OS; Hong SK; Kwon SJ; Go YH; Oh E; Cha HJ
    Cancer Lett; 2017 Sep; 403():48-58. PubMed ID: 28606806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
    Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
    Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of triple negative breast cancer cells with combination of mTOR1/2 inhibitor AZD8055 and MEK1/2 inhibitor PD0325901].
    Nan XY; Wu Y; Zhang LH; Yang ZJ
    Yao Xue Xue Bao; 2016 Oct; 51(10):1551-7. PubMed ID: 29932599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
    Hong SK; Wu PK; Karkhanis M; Park JI
    Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy.
    Li X; Hou J; Wang C; Liu X; He H; Xu P; Yang Z; Chen Z; Wu Y; Zhang L
    Molecules; 2013 Nov; 18(11):13957-78. PubMed ID: 24225774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.
    Han S; Zhou V; Pan S; Liu Y; Hornsby M; McMullan D; Klock HE; Haugen J; Lesley SA; Gray N; Caldwell J; Gu XJ
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5467-73. PubMed ID: 16199156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2.
    Zheng CF; Guan KL
    J Biol Chem; 1993 May; 268(15):11435-9. PubMed ID: 8388392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
    Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
    Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome mapping of the human genes encoding the MAP kinase kinase MEK1 (MAP2K1) to 15q21 and MEK2 (MAP2K2) to 7q32.
    Meloche S; Gopalbhai K; Beatty BG; Scherer SW; Pellerin J
    Cytogenet Cell Genet; 2000; 88(3-4):249-52. PubMed ID: 10828601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
    Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
    Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.